NEXGEL, Inc. (NXGL)
| Market Cap | 22.04M |
| Revenue (ttm) | 8.69M |
| Net Income (ttm) | -3.28M |
| Shares Out | 7.65M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,345 |
| Open | 3.090 |
| Previous Close | 3.050 |
| Day's Range | 2.855 - 3.090 |
| 52-Week Range | 1.840 - 5.100 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 24, 2025 |
About NXGL
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incis... [Read more]
Financial Performance
In 2024, NEXGEL's revenue was $8.69 million, an increase of 112.47% compared to the previous year's $4.09 million. Losses were -$3.28 million, 3.93% more than in 2023.
Financial StatementsNews
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executiv...
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Exe...
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing
NEXGEL Announces $2,000,000 Registered Direct Offering
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...
NEXGEL to Participate in Upcoming October Investor Conferences
LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executi...
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and...
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...
NEXGEL Acquires International Beauty Brand, Silly George
Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIR...
NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Adam Levy - Chief Executive Off...
NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript
NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript
NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare an...
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, ...
NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, ...
NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
LANGHORNE, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
LANGHORNE, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...